15 Best Long-Term Healthcare Stocks to Invest in for 2025

Why Invest in Healthcare Stocks in 2025

The healthcare industry trends 2025 remains a top choice for investors who want to invest for the long term during 2025. Here’s why:

Growing Global Demand

The worldwide demand for medical products and services continues to rise because of aging populations and increasing chronic diseases and expanding healthcare access in emerging markets. The growing healthcare stocks trend enables numerous healthcare companies to achieve consistent revenue expansion.

Innovation Driving Growth

The industry experiences transformation through recent breakthroughs in biotechnology pharmaceuticals and medical technology. The companies leading these innovations present substantial growth potential because they bring new treatments and devices to market.

A Balanced Investment Opportunity

Healthcare stands as a unique industry which unites defensive characteristics with promising growth prospects. The sector performs well during uncertain market conditions and provides access to innovative developments which makes it an excellent selection for diversified long-term investment healthcare stocks portfolio.

How These Healthcare Stocks Were Selected

The selection of appropriate healthcare stocks needs thorough evaluation. The selection process for top 2025 healthcare stocks involved these specific criteria.

• Strong Innovation Pipeline and Product Approvals: Companies with approved new treatments and drugs and medical devices in their pipeline together with recent regulatory approvals indicate future growth potential.

• Financial Health and Profitability Metrics: Our selection process focused on companies that maintain strong financial health through solid balance sheets and consistent profitability and efficient cash flow management for long-term stability.

• Analyst Sentiment and Market Momentum: The selection process included stocks that received positive recommendations from industry experts and demonstrated positive market trends because they showed strong investor confidence and momentum.

• Valuation Metrics and Long-Term Growth Outlook: The evaluation process involved stock price analysis against earnings data and growth projections to identify companies with affordable valuations and promising future growth potential.

• Impact of Recent Earnings and Regulatory Developments: The evaluation process emphasized companies that achieved strong recent earnings performance and received beneficial regulatory changes.

What Are the Best Healthcare Stocks to Buy?

The following list includes 15 top long-term healthcare stocks for 2025 investment based on their strong growth potential and solid fundamentals.

1. Samsung Biologics (207940.KQ)

2. AbbVie Inc. (ABBV)

3. Johnson & Johnson (JNJ)

4. Celltrion, Inc. (068270.KQ)

5. Novartis AG (NVS)

6. Medtronic Plc (MDT)

7. AstraZeneca plc (AZN)

8. Divi’s Laboratories Ltd.

9. Sanofi S.A. (SNY)

10. Roche Holding AG (RHHBY)

11. GlaxoSmithKline plc (GSK)

12. Takeda Pharmaceutical Company (4502.T)

13. Pfizer Inc. (PFE)

14. Dr. Reddy’s Laboratories Ltd. (RDY)

15. Astellas Pharma Inc. (4503.T)

List of Best Healthcare Stocks Worldwide (2025) - Detailed Explanation

Healthcare stands as the leading sector for sustained expansion throughout 2025. The table presents selected global healthcare stock growth potential 2025 which include their price range and country of origin and sector classification and investment rationale.

Samsung Biologics (207940.KQ)

Current Price (1 September 2025): $715.75

Samsung Biologics is South Korea's primary biopharmaceutical contract development and manufacturing organization (CDMO).

The company delivers complete services that span from drug development to manufacturing and biosafety testing for biologic drugs.

The company maintains a vital position in worldwide biotech supply chain operations through its extensive manufacturing capabilities and extensive international customer network.

Key Details:

• Market Cap: $52.3 billion

• P/E Ratio: 75.8

• Revenue (TTM): $2.97 billion

• YoY Growth: 33%

Investor Appeal:

The global CDMO powerhouse Samsung Biologics demonstrates consistent revenue growth through high-margin contracts and strategic partnerships with major pharmaceutical companies.

The company's ability to scale operations combined with its innovative biologics manufacturing capabilities and biosimilars and mRNA production expansion makes it a long-term winner in the global healthcare industry.

AbbVie Inc. (ABBV)

Current Price (1 September 2025): $210.40

AbbVie is a U.S.-based global biopharmaceutical company which gained fame through its successful immunology drugs including Humira, Skyrizi and Rinvoq.

The company maintains a solid position in oncology, neuroscience and aesthetics while expanding through strategic acquisitions and developing its product pipeline.

Key Details:

• Market Cap: $364.2 billion

• P/E Ratio: 16.5

• Revenue (TTM): $63.1 billion

• YoY Growth: 8.7%

Investor Appeal:

The company provides investors with both strong dividend payments and growth potential through its high dividend yield and consistent earnings performance.

The company's ability to move past Humira through new drug development and Allergan acquisition makes it a solid healthcare stocks long-term investment choice for investors who want dependable returns from large pharmaceutical companies.

Johnson & Johnson (JNJ)

Current Price (1 September 2025): $177.17

Johnson & Johnson is one of the world's biggest healthcare companies which extends its operations through pharmaceuticals and medical devices and consumer health divisions.

The spin-off of consumer division Kenvue enables J&J to concentrate on high-margin innovation-driven areas including oncology, immunology and surgical technologies.

Key Details:

• Market Cap: $429.6 billion

• P/E Ratio: 15.2

• Revenue (TTM): $87.6 billion

• YoY Growth: 5.2%

Investor Appeal:

Johnson & Johnson is a blue-chip healthcare stock which provides stability through consistent dividend payments and maintains a broad economic moat.

The company's diversified business model combined with its strong research and development pipeline makes it an attractive defensive long-term core investment during market volatility.

Celltrion, Inc. (068270.KQ)

Current Price (1 September 2025): $134.90

Celltrion is a South Korean biopharmaceutical organization which focuses on developing and manufacturing biosimilars together with innovative biologics.

The company leads the world in biosimilar production through its approved medications Remsima, Truxima and Herzuma while it continues to develop its pipeline for autoimmune diseases and oncology and infectious diseases.

Key Details:

• Market Cap: $22.4 billion

• P/E Ratio: 38.7

• Revenue (TTM): $1.85 billion

• YoY Growth: 17.5%

Investor Appeal:

Celltrion leverages worldwide biosimilar market demand through its state-of-the-art biomanufacturing facilities. The company's expanding international regulatory approvals together with its affordable manufacturing processes and entry into fresh therapeutic markets positions it as a promising high-growth healthcare stock across Asia and worldwide.

Novartis AG (NVS)

Current Price (1 September 2025): $126.55

The Swiss multinational pharmaceutical company Novartis AG is a leading organization which develops innovative medicines for oncology and immunology and neuroscience and cardiovascular diseases.

The company maintains its worldwide operations through R&D investments while its lean structure results from the Sandoz generics unit spin-off.

Key Details:

• Market Cap: $268.9 billion

• P/E Ratio: 14.7

• Revenue (TTM): $53.4 billion

• YoY Growth: 6.3%

Investor Appeal:

The company provides both innovative products and financial stability through its advanced pipeline development and operational efficiency improvements.

The company maintains a strong position as a global healthcare stock * investment through its focus on high-margin patented drugs and its consistent dividend payments.

Medtronic Plc (MDT)

Current Price (1 September 2025): $92.81

Medtronic is one of the world's leading medical device companies with its headquarters in Ireland while maintaining operations across the globe.

The company focuses on developing sophisticated medical technologies which include cardiac care solutions and neuromodulation systems and diabetes management tools and surgical equipment for worldwide hospital and healthcare provider markets.

Key Details:

• Market Cap: $118.2 billion

• P/E Ratio: 16.1

• Revenue (TTM): $32.7 billion

• YoY Growth: 4.5%

Investor Appeal:

The healthcare stock Medtronic is a defensive company with stable cash flows and diverse product range and reliable dividend payments.

The company maintains its position for future growth through its worldwide reach and its focus on developing minimally invasive and robotic surgical technologies which serve aging and emerging markets.

AstraZeneca plc (AZN)

Current Price (1 September 2025): $79.90

AstraZeneca is a British-Swedish multinational pharmaceutical company which develops innovative medicines for oncology cardiovascular respiratory and immunology applications.

The company has achieved worldwide recognition through its COVID-19 vaccine development while building a robust pipeline of future-generation treatments.

Key Details:

• Market Cap: $210.5 billion

• P/E Ratio: 23.4

• Revenue (TTM): $47.2 billion

• YoY Growth: 12.8%

Investor Appeal:

AstraZeneca achieves strong pipeline expansion while its global sales increase mainly through oncology and rare disease segments.

The company's dedication to innovation together with its strategic partnerships makes it an attractive healthcare stock investment option for investors who want pharma growth in the long term.

Divi’s Laboratories Ltd.

Current Price (1 September 2025): $68.68

The Indian pharmaceutical company Divi’s Laboratories is a major worldwide producer of active pharmaceutical ingredients (APIs) and custom synthesis services which deliver products to leading drug manufacturers across the globe.

Divi’s stands out for its high-quality products and economical manufacturing methods which make it essential for worldwide pharmaceutical supply operations to provide affordable essential medicines.

The company produces APIs for oncology and cardiovascular treatments as well as anti-diabetic and antibiotic medications through its diverse product range.

Key Details:

• Market Cap: $7.1 billion

• P/E Ratio: 28.6

• Revenue (TTM): $540 million

• YoY Growth: 18.3%

Investor Appeal:

The rising worldwide need for cost-effective high-quality APIs drives Divi’s Laboratories toward growth. The company maintains its position as a dependable long-term pharma supply chain investment because of its robust manufacturing operations and growing customer network and dedication to innovation.

Sanofi S.A. (SNY)

Current Price (1 September 2025): $49.48

Sanofi is a leading French multinational pharmaceutical company which delivers vaccines and specialty care solutions and diabetes management products and consumer healthcare solutions.

Sanofi Pasteur is the world's leading vaccine manufacturer through its vaccine division which distributes essential immunizations worldwide.

The company dedicates significant funds to research and development for rare diseases and oncology and immunology while building its pipeline with new innovative treatments.

Key Details:

• Market Cap: $127.3 billion

• P/E Ratio: 15.8

• Revenue (TTM): $44.5 billion

• YoY Growth: 4.9%

Investor Appeal:

The pharmaceutical company Sanofi provides investors with a solid healthcare investment through its stable cash flows from vaccines and established drugs while offering promising growth potential in specialty care and rare diseases.

The pharmaceutical company presents an attractive investment opportunity because it has a broad international reach and innovative focus and pays dividends to investors who want pharmaceutical sector growth with income generation.

Roche Holding AG (RHHBY)

Current Price (1 September 2025): $40.77

Roche Holding AG is a Swiss multinational healthcare company which stands as a worldwide leader in pharmaceuticals and diagnostics.

The company focuses on oncology and immunology and infectious diseases and personalized medicine through its innovative pharmaceuticals and diagnostic solutions.

The diagnostics division of Roche supports its pharmaceutical business through advanced testing technologies which enable precision medicine.

Key Details:

• Market Cap: $250 billion

• P/E Ratio: 17.8

• Revenue (TTM): $65 billion

• YoY Growth: 7.1%

Investor Appeal:

Roche provides investors with a stable investment opportunity through its innovative targeted therapies and diagnostic solutions.

The company's commitment to personalized healthcare and precision medicine creates a solid foundation for future expansion.

Roche's consistent dividend payments make it an attractive choice for investors who want to invest in global healthcare innovation while seeking income.

GlaxoSmithKline plc (GSK)

Current Price (1 September 2025): $39.67

GlaxoSmithKline is a leading British pharmaceutical company which produces vaccines and pharmaceuticals and consumer healthcare products.

The company has been focusing on strengthening its vaccine and specialty medicines segments, including respiratory and HIV treatments, while recently spinning off its consumer health business to focus more on innovation-driven growth.

Key Details:

• Market Cap: $90 billion

• P/E Ratio: 14.9

• Revenue (TTM): $38 billion

• YoY Growth: 5.8%

Investor Appeal:

The company provides investors with stable earnings and expansion opportunities through its vaccine leadership position and developing specialty drug portfolio.

The company's research and development focus on immunology and oncology together with its dividend yield make it an attractive investment opportunity for those seeking long-term healthcare investments.

Takeda Pharmaceutical Company (4502.T)

Current Price (1 September 2025): $30.44

Takeda Pharmaceutical is a Japan's leading pharmaceutical company while maintaining a worldwide reach through its gastroenterology and oncology and neuroscience and rare diseases focus.

Takeda achieved growth in high-value therapeutic areas through its strategic acquisition of Shire which led to expanded specialty drug offerings and enhanced R&D capabilities.

Key Details:

• Market Cap: $46.7 billion

• P/E Ratio: 18.2

• Revenue (TTM): $31.5 billion

• YoY Growth: 6.5%

Investor Appeal:

The company provides investors with a diverse investment opportunity through its strong presence in specialty pharmaceuticals and rare diseases.

The company's strong pipeline combined with its global reach and dedication to innovation positions it for long-term growth.

The company's moderate dividend yield provides income benefits to investors who plan to hold their investments for the long term.

Pfizer Inc. (PFE)

Current Price (1 September 2025): $24.76

Pfizer Inc. is a major pharmaceutical company based in the United States which develops innovative medicines and vaccines for different therapeutic fields including oncology, cardiology, immunology and infectious diseases.

The company achieved worldwide recognition through its COVID-19 vaccine development while it continues to build its pipeline with innovative treatments and strategic business acquisitions.

Key Details:

• Market Cap: $220 billion

• P/E Ratio: 12.5

• Revenue (TTM): $100 billion

• YoY Growth: 7.4%

Investor Appeal:

Pfizer provides investors with a powerful mix of innovative products and large market presence and profitable operations.

The company provides investors with a reliable healthcare investment opportunity through its diverse product range and active pipeline development and regular dividend payments.

Dr. Reddy’s Laboratories Ltd. (RDY)

Current Price (1 September 2025): $14.20

Dr. Reddy’s Laboratories is a leading Indian pharmaceutical firm which develops generic medicines alongside biosimilars and active pharmaceutical ingredients (APIs).

The company operates worldwide through its extensive presence in the U.S. and Europe and emerging economies to provide affordable healthcare solutions.

Key Details:

• Market Cap: $5.4 billion

• P/E Ratio: 22.1

• Revenue (TTM): $2.1 billion

• YoY Growth: 12.0%

Investor Appeal:

The company provides stable growth opportunities through its expanding biosimilars portfolio and its growing presence in regulated markets. The company's strong R&D efforts and strategic partnerships drive innovation and competitiveness which makes it an attractive option for investors who want to invest in emerging market pharmaceuticals.

Astellas Pharma Inc. (4503.T)

Current Price (1 September 2025): $11.19

Astellas Pharma is a major Japanese pharmaceutical organization which focuses on developing treatments for oncology, urology, immunology and neuroscience.

Astellas Pharma dedicates significant resources to research and development because it focuses on creating innovative treatments that solve unmet medical requirements across the globe.

The company maintains a diverse pipeline with promising late-stage candidates that focus on cancer immunotherapy and regenerative medicine.

Key Details:

• Market Cap: $25.8 billion

• P/E Ratio: 14.3

• Revenue (TTM): $11.9 billion

• YoY Growth: 5.7%

Investor Appeal:

Astellas achieves steady revenue growth through its expanding specialty drug portfolio and strategic partnerships that increase its global presence.

The pharmaceutical company Astellas offers investors a moderate dividend yield which provides income potential while delivering growth and stability in the pharmaceutical sector.

Types of Healthcare Stocks

Healthcare stocks include major pharmaceutical companies as well as biotech startups and medical device manufacturers. The following list presents the main investment options for consideration.

Large-cap Pharmaceutical Companies

These are established pharmaceutical giants with broad product lines and global reach. They provide stable earnings and often pay dividends, making them ideal for conservative investors seeking steady income and lower risk.

Biotech Innovators and Emerging Drug Developers

The market includes smaller high-growth companies which focus on developing new therapies through advanced scientific methods including gene editing. The stocks demonstrate high volatility yet provide substantial growth opportunities when their drugs achieve success.

Medical Device and Technology Companies

Medical instrument manufacturers together with diagnostic tool producers and healthcare technology developers form this sector. The sector benefits from worldwide healthcare spending growth and innovation which leads to steady expansion.

Healthcare ETFs for Diversified Investment

ETFs distribute their investments across various healthcare sectors which provides investors with diversified exposure while minimizing the risks associated with individual stock investments. The ETF provides investors with a simple way to access the healthcare market.

Healthcare Market Outlook (2025–2030)

Healthcare will experience substantial growth and transformation during the next decade until 2030. The healthcare industry will undergo significant changes because of aging populations and new technologies and emerging markets.

Global Aging Population and Increasing Healthcare Demand

The aging population worldwide will drive substantial growth in healthcare service and product requirements. The medical needs of older adults drive market expansion in chronic disease management and long-term care and pharmaceutical sectors.

Innovation Trends: Gene Therapy, AI in Diagnostics, Digital Health

Gene therapy represents one of the modern breakthroughs which provides treatment options for diseases that were once untreatable.

Artificial intelligence revolutionizes diagnostic procedures through its ability to detect health conditions at a faster rate with higher precision.

Digital health technologies through telemedicine and wearable devices enhance patient monitoring and improve healthcare accessibility.

Opportunities in Emerging Markets and Specialized Therapies

The growth of emerging markets becomes possible because of increasing incomes and better healthcare systems. The market for rare disease treatments and personalized medicine continues to expand as these specialized therapies gain popularity which creates new investment opportunities.

Risks & Considerations for Healthcare Investors

Healthcare investing faces regulatory challenges and clinical trial uncertainties which affect valuation outcomes.

The sector operates with high market volatility and intense competition which causes stock prices to react to news and market fluctuations.

The revenue of companies depends on regulatory and policy changes in drug pricing and reimbursement rules so it is essential to monitor these developments.

Tips to Build a Healthcare Portfolio

A healthcare portfolio requires diversification and continuous monitoring of industry news to achieve strength. The strategy enables risk management while accessing growth potential.

• Diversify across pharmaceutical, biotech, and medical technology sectors: Investing in multiple healthcare subsectors enables risk reduction and growth potential capture across different industry segments.

• Invest in a balance of large-cap companies: Large pharmaceutical firms generate stable income and exhibit lower volatility yet smaller biotech and med-tech companies present higher growth potential with elevated risk levels.

• Stay informed on regulatory updates: The ability to track essential developments enables investors to predict market movements which leads to better timing of their investment choices because these factors strongly affect stock performance.

Conclusion

Healthcare stocks present a promising combination of high growth potential and defensive characteristics which makes them suitable for investors who want both innovative exposure and long-term stability during 2025.

Healthcare stock investment success requires continuous research together with strategic diversification and risk management techniques to handle sector challenges and achieve maximum returns.